Table 3.

Spearman rank correlation analysis.

Variable		Validation cohort (n = 120)
		miR-216a (n = 106)	miR-155 (n = 78)
Metabolic Syndrome	r	−0.104	−0.047
	p	0.292	0.687
Metabolic Syndrome score	r	−0.185	−0.152
	p	0.060	0.192
Age (years)	r	0.107	0.033
	p	0.279	0.776
Weight (kg)	r	−0.165	−0.195
	p	0.095	0.093
Height (cm)	r	0.061	0.046
	p	0.541	0.695
BMI (kg/m2)	r	−0.200	−0.161
	p	*0.042	0.168
Waist circumference (cm)	r	−0.223	−0.161
	p	*0.023	0.168
SBP (mmHg)	r	−0.170	−0.064
	p	0.084	0.584
DBP (mmHg)	r	−0.202	−0.750
	p	*0.039	0.523
MAP (mmHg)	r	−0.206	−0.052
	p	*0.036	0.655
heart rate (bpm)	r	−0.07	0.005
	p	0.483	0.967
Total Cholesterol (mmol/L)	r	−0.107	−0.048
	p	0.281	0.681
HDL Cholesterol (mmol/L)	r	0.190	0.086
	p	0.054	0.464
LDL Cholesterol (mmol/L)	r	−0.145	−0.096
	p	0.141	0.415
Triglycerides (mmol/L)	r	−0.201	−0.168
	p	*0.041	0.149
Total cholesterol/HDL	r	−0.225	−0.144
	p	*0.021	0.218
Fasting Glucose (mmol/L)	r	0.004	0.108
	p	0.966	0.354
Insulin (mmol/L)	r	−0.162	−0.115
	p	0.101	0.330
GFR (mL/min/1.73m2)	r	−0.017	−0.099
	p	0.862	0.400
Uric Acid (mmol/L)	r	−0.165	−0.110
	p	0.094	0.348
Microalbuminuria (g/mol Creat)	r	−0.040	−0.210
	p	0.686	0.071
hs-CRP (mg/L)	r	−0.271	−0.179
	p	**0.006	0.130
Leucocytes (10∧9/L)	r	−0.076	−0.145
	p	0.449	0.221
Fibronectin (mg/L)	r	−0.114	−0.021
	p	0.257	0.858
Fibrinogen (g/L)	r	−0.154	−0.237
	p	0.121	*0.040

Relationship between miR-216a, miR-155, and factors constituting metabolic risk in the validation cohort (n = 120). miR-216a was detectable in 106 samples of the validation cohort, while miR-155–5p was detected in 78 samples of the validation cohort. r, Spearman rank correlation coefficient; p, p-value; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; GFR glomerular filtration rate; hs- CRP, high sensitivity C-reactive protein.